The length of the patent term extension is related to the length of time the drug is under regulatory review.Source

However, the term of United States patents may be extended for delays incurred due to compliance with the FDA requirements or by delays encountered during prosecution that are caused by the United States Patent and Trademark Office, or the USPTO.Source

We intend to seek patent term extensions to any of our issued patents in any jurisdiction where these are available; however, there is no guarantee that the applicable authorities, including the USPTO and FDA, will agree with our assessment of whether such extensions should be granted.Source

The term of individual patents depends upon the laws of the countries in which they are obtained.Source

The term of a patent that covers an FDA-approved drug may also be eligible for patent term extension, which permits patent term restoration of a U.S. patent as compensation for the patent term lost during the FDA regulatory review process.Source

We expect the issued composition of matter patent to expire in 2034 (worldwide, excluding possible patent term extensions).Source

We expect any composition of matter or methods patents, if issued from the pending patent applications, and if the appropriate maintenance, renewal, annuity or other governmental fees are paid, to expire from 2037-2039 (worldwide, excluding possible patent term extensions).Source

As of February 8, 2023, we owned 9 patent families that include 4 issued U.S. patents, 10 pending U.S. patent applications, 6 corresponding foreign patents, and 56 corresponding foreign patent applications related to our gene-editing platform.Source

The term of individual patents depends upon the legal term for patents in the countries in which they are granted.Source

We expect that any patents that may issue in this family would expire in December 2042.Source

Generally, patents issued for applications filed in the United States are effective for 20 years from the earliest effective filing date.Source

Individual patents extend for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained.Source

If patents are issued on our pending patent applications, the resulting patents are projected to expire on dates ranging from 2036 to 2043, unless we receive patent term extension or patent term adjustment, or both.Source

For drugs that are regulated by the FDA under the Hatch-Waxman Act, it is permitted to extend the term of a patent that covers such drug for up to five years beyond the normal expiration date of the patent.Source

However, the term of United States patents may be extended for delays incurred due to compliance with the FDA requirements or by delays encountered during prosecution that are caused by the United States Patent and Trademark Office (the “USPTO”).Source

In most countries in which we file, the patent term is 20 years from the earliest date of filing of a non-provisional patent application.Source

We built the world's first and only true AI-driven precision medicine platform, called Clarity. And now Clarity in and of itself is really a game-changing technology, as it combines potentially millions of data points from 700,000 unique genes and blood biomarkers, microbiome data, phenotypic data, subjective feedback from patients and even data from wearables.

Our vision, WildHealth and LivePerson together, is to take the highest quality health outcomes in the world and scale that to millions of people.

Additionally, the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) permits patent term extension of up to five years beyond the expiration date of a U.S. patent as partial compensation for the length of time a drug is under regulatory review while a patent that covers the drug is in force.Source

In most countries in which we file, the patent term is generally 20 years from the earliest date of filing a non-provisional patent application.Source

The length of the patent term extension is related to the length of time the drug is under regulatory review.Source

In the future, if and when our drug candidates receive approval by the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those products, if available.Source

For example, for drugs that are regulated by the FDA under the Hatch-Waxman Act, it is permitted to extend the term of a patent that covers such drug for up to five years beyond the normal expiration date of the patent.Source

However, the term of United States patents may be extended for delays incurred due to compliance with the FDA requirements or by delays encountered during prosecution that are caused by the USPTO.Source

In the future, if and when our biopharmaceutical product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates.Source

However, the term of United States patents may be extended for delays incurred due to compliance with the FDA requirements or by delays encountered during prosecution that are caused by the USPTO.Source